You are here

Cloned pigs for Xenotransplantation

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI069865-01
Agency Tracking Number: AI069865
Amount: $166,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2006
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
EVERGEN BIOTECHNOLOGIES, INC. 1392 STORRS RD, UNIT 4213
STORRS, CT 06296
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 XIANGZHONG YANG
 (860) 486-2406
 JYANG@CANR.CAG.UCONN.EDU
Business Contact
Phone: (860) 486-2526
Research Institution
 UNIVERSITY OF CONNECTICUT
 
UNIVERSITY OF CONNECTICUT
STORRS, CT 06268
United States

 Nonprofit college or university
Abstract

DESCRIPTION (provided by applicant): The purpose of the proposed research is to develop methods to create immune protected universal donor cloned transgenic pigs for xenotransplantation. According to the United Network of Organ Sharing (UNOS) more than 30,000 organ transplants are performed in the US alone, yet greater than 95,000 people are currently on the waiting list to receive donors organs for the treatment of end-stage organ failure. Current strategies to increase the pool of donor organs available for transplantation has only led to marginal increases that are insufficient to satisfy the growing need for donor organs and tissues. Many clinical investigators, large international pharmaceutical companies as well as several biotechnology companies have looked to develop transgenic pigs as a source of universal donor tissue. Therefore, the goal of this research plan for the Phase I STTR, is to perfect nuclear transfer with primary cell lines derived from previously cloned animals containing the human H-transferase gene and a homozygous targeted mutation of the porcine Gal-alpha1,3Gal transferase gene (GT-/-HT) into in vitro cultured pig oocytes. Primary embryonic fibroblasts and embryonic neural stem cells will be tested to determine which cell type is the best nuclear donor in in vitro nuclear transfer experiments by assessing blastocyst development (Experiment 1). Subsequently, the cell type from Experiment 1 that is most efficacious in producing blastocysts will be genetically modified with a bi-functional chimeric molecule (CD152-CD59) that inhibits both humoral and cellular immune responses to transplanted tissues. We will select transfected cell clones and analyze the cells in vitro to asses expression levels and the function of the transfected gene product. Different transfected cell clones will then be selected for follow-on nuclear transfer experiments to demonstrate blastocyst formation in vitro from the transfected cells. Demonstrating blastocyst development in vitro from cells derived from a previously cloned transgenic pig that are then genetically modified further with a molecule designed to resist immune destruction will provide the necessary data to support a Phase II STTR research proposal for developing cloned living animals that could then be used to assess survival in in vivo transplant models, which could eventually lead to clinical transplantation applications.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government